Table 1.
Study and baseline patient characteristics of the included study populations
| Derivation population | External validation and testing populations |
||||||
|---|---|---|---|---|---|---|---|
| CONOR | ARIC | CPRD | HYVET | MESA | PROSPER | SPRINT | |
| N = 28 503 | N = 5153 | N = 319 390 | N = 3381 | N = 2977 | N = 3254 | N = 4460 | |
| Recruitment period | 1994–2003 | 2011–2013 | 2006a | 2001–2007 | 2000–2002 | 1997–1999 | 2010–2013 |
| Country | Norway | USA | UK | Eastern Europe (n = 1895), Western Europe (n = 84), others (n = 1402) | USA | UK (n = 1288), Ireland (n = 1339), Netherlands (n = 627) | USA |
| Baseline characteristics | |||||||
| Male sex (%) | 50 | 39 | 42 | 38 | 48 | 42 | 59 |
| Age (years) | 73 ± 5 | 75 ± 5 | 74 ± 6 | 83 ± 3 | 72 ± 5 | 75 ± 3 | 74 ± 6 |
| Current smoking (%) | 20 | 7 | 25 | 7 | 8 | 33 | 5 |
| SBP (mmHg) | 152 ± 23 | 130 ± 18 | 141 ± 16 | 173 ± 9 | 134 ± 22 | 157 ± 21 | 141 ± 15 |
| Total cholesterol (mmol/L) | 6.4 ± 1.2 | 4.8 ± 1.1 | 5.5 ± 1.2 | 5.3 ± 1.1 | 5.0 ± 0.9 | 5.7 ± 0.9 | 4.9 ± 1.0 |
| HDL cholesterol (mmol/L) | 1.5 ± 0.4 | 1.4 ± 0.4 | 1.6 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 | 1.3 ± 0.4 | 1.4 ± 0.4 |
| Type 2 diabetes mellitus (%) | 6 | 31 | 10 | 9 | 15 | 12 | 0 |
| Lipid-lowering drugs use (%) | 9 | 49 | 21 | 0.3 | 22 | 49 | 44 |
| Median follow-up (IQI) | 13 (8–15) | 6 (5–6) | 7 (4–10) | 2 (1–3) | 13 (9–14) | 3 (3–4) | 3 (3–4) |
| Primary endpoint | 10 089 (35%) | 427 (8%) | 31 484 (10%) | 225 (7%) | 501 (17%) | 396 (12%) | 186 (4%) |
| Total mortality | 16 642 (58%) | 683 (13%) | 60 077 (19%) | 356 (11%) | 981 (33%) | 274 (8%) | 194 (4%) |
All data are expressed in n (%) or mean ± standard deviation unless stated otherwise.
a
Baseline for measurement of exposure was set at 1 January 2006.
HDL, high-density lipoprotein; IQI, interquartile interval; SBP, systolic blood pressure; CV, cardiovascular, IQR, interquartile range.